Kim C Ohaegbulam, B.S.
Department of Microbiology & Immunology
Albert Einstein College of Medicine
Forchheimer Building, Room 405
Bronx, NY 10461
Kim Ohaegbulam received his B.S. from the University of South Florida Honors College, where he majored in the Biomedical Sciences. During that time, he worked in the laboratory of Dr. Scott J. Antonia at the Moffitt Cancer Center enhancing the efficacy of immunotherapy in lung cancer mouse models. Kim joined the Albert Einstein College of Medicine MSTP in 2010 and is currently in the Zang laboratory studying new pathways for T cell costimulation and coinhibition and related diseases.
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 21:24-33, 2015
Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clinical Cancer Research, 21:2359-2366, 2015
Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Structure and cancer immunotherapy of the B7 family member B7x. Cell Reports, 9:1089-1098, 2014
Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Proceedings of the National Academy of Sciences USA, 110:9879-9884, 2013.
Jeon H, Ohaegbulam KC, Abadi YM, Zang X. B7x(B7-H4/B7S1) and myeloid derived suppressor cells in the tumor microenvironment: A tale of two cities. OncoImmunology, e24744-1-e24744-3, 2013
Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X. Host B7x promotes pulmonary metastasis of breast cancer. The Journal of Immunology, 190:3806-3814, 2013